Home
Scholarly Works
Dupilumab Add-on to Medium-dose Inhaled...
Conference

Dupilumab Add-on to Medium-dose Inhaled Corticosteroid (ICS) Increases Odds of Asthma Control and Reduces FeNO Compared With Placebo Add-on to High-dose ICS

Authors

Busse W; Castro M; Lugogo NL; O'Byrne PM; Bacharier LB; Xia C; Hardin M; Soliman M; Sacks H; Jacob-Nara JA

Volume

209

Publisher

AMER THORACIC SOC

Publication Date

May 1, 2024

Name of conference

International Conference of the American-Thoracic-Society (ATS)

Conference place

CA, San Diego

Conference start date

May 17, 2024

Conference end date

May 22, 2024

Conference proceedings

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

ISSN

1073-449X

Contact the Experts team